⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Alvotech and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Alvotech
↗Luxembourg, Luxembourg
Alvotech is a global biopharmaceutical company focused exclusively on the development and manufacture of high-quality biosimilar medicines for patients worldwide. Founded in 2013, the company utilizes a fully integrated, end-to-end business model that spans from cell line development to large-scale commercial manufacturing.
Headquartered in Luxembourg with significant R&D and manufacturing operations in Reykjavik, Iceland, Alvotech aims to improve patient access to affordable biologic treatments. Its pipeline targets serious diseases across therapeutic areas including immunology, ophthalmology, bone disorders, and oncology.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$500M-$600M
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Oaktree Capital Management
STOCK
Exchange:NASDAQ
Ticker:ALVO
Market Cap:$1.22B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:mAb, Biosimilars
Trial Phases:-
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Key Partnerships:Teva Pharmaceutical Industries (Commercialization partner), Advanz Pharma (Commercialization partner), Dr. Reddy's Laboratories (Collaboration)
COMPETITION
Position:Challenger
Competitors:Amgen, Sandoz, Biocon Biologics, Samsung Bioepis
LEADERSHIP
Key Executives:
Róbert Wessman - Founder & Chairman
Balaji Prasad - Chief Strategy Officer
Scientific Founders:Róbert Wessman
LINKS
Website:alvotech.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Alvotech. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.